Denmark, Norway and Iceland have entered into cooperation regarding the procurement of pharmaceuticals. The countries will jointly procure and award framework agreements in order to ensure the supply of pharmaceuticals to the public hospitals and health authorities in the countries. In Denmark certain pharmaceuticals are resold to the Faroe Island and Greenland.
The obligation to deliver the pharmaceuticals in Iceland is subject to the precondition that the supplier obtains an exemption regarding printed labels and leaflets. If the supplier does not obtain such exemption the agreement will only apply to Denmark and Norway, see the framework agreement section 2.2.1 and Appendix 6.
The framework agreements are non-exclusive to the supplier. The hospitals and health authorities are not obliged to use the framework agreement.
ATC Code: J01CA01
Generic name: Ampicilline
Pharmaceutical form: Injection fluid
Strength: 1 g
Unit: 6 g
Volume in units: (Denmark 12.525) (Norway: 12.646) (Iceland: 3.166)
ATC Code: J01CA01
Generic name: Ampicilline
Pharmaceutical form: Injection fluid
Strength: 2 g
Unit: 6 g
Volume in units: (Denmark 47.579) (Norway: 149.333) (Iceland: 10)
Each procurement number is a separate lot for the pharmaceutical indicated and is put up for tender independently of the other procurement numbers. This means that a tenderer may submit a tender for one, several or all procurement numbers (lots), and that framework agreements will be awarded separately for each procurement number. Reference is made to the tender specifications, including the provision on the list of products in general.
Under the title ‘quantity in units’, an estimated consumption of the pharmaceuticals is indicated for each of the countries. It should be noted that this estimate corresponds to the historical consumption of the pharmaceuticals put up for tender and that suppliers must expect that the actual purchase under a framework agreement may deviate significantly from the estimate. Reference is made to paragraph 5.6 of the tender specifications and clause 4.2 in the framework agreement.
The Supplier must have authorisation to produce, import or receive pharmaceuticals for wholesale distribution within the EU/EEA.
The Pharmaceuticals shall be included in the Danish Medicines Agency’s list of medicine prices (‘medicinpriser.dk’) and the Norwegian ‘Farmalogg’ and the Icelandic ‘Lyfjaverðskrá’ not later than 7 February 2022 in order to ensure supply from the beginning of the purchase period.
Procurement no.: 10
ATC Code: J01XD01
Generic name: Metronidazol
Pharmaceutical form: Infusion fluid
Strength: 5 mg/ml
Package:
Unit: 1,5 g
Volume in units: (Denmark 293.320) (Norway: 152.207) (Iceland: 10.333)
Each procurement number is a separate lot for the pharmaceutical indicated and is put up for tender independently of the other procurement numbers. This means that a tenderer may submit a tender for one, several or all procurement numbers (lots), and that framework agreements will be awarded separately for each procurement number. Reference is made to the tender specifications, including the provision on the list of products in general.
Under the title "quantity in units", an estimated consumption of the pharmaceuticals is indicated for each of the countries. It should be noted that this estimate corresponds to the historical consumption of the pharmaceuticals put up for tender and that suppliers must expect that the actual purchase under a framework agreement may deviate significantly from the estimate. Reference is made to paragraph 5.6 of the tender specifications and clause 4.2 in the framework agreement.
The Supplier must have authorisation to produce, import or receive pharmaceuticals for wholesale distribution within the EU/EEA.
The Pharmaceuticals shall be included in the Danish Medicines Agency’s list of medicine prices (“medicinpriser.dk”) and the Norwegian “Farmalogg” and the Icelandic “Lyfjaverðskrá” not later than 7 February 2022 in order to ensure supply from the beginning of the Purchase Period.
Procurement no.: 2
ATC Code: J01DC02
Generic name: Cefuroxime
Pharmaceutical form: Duplex infusionbag
Strength: 1500 mg
Unit: 3 g
Volume in units: (Denmark 104.928) (Norway: 12.000) (Iceland: 10)
ATC Code: J01DC02
Generic name: Cefuroxime
Pharmaceutical form: Duplex infusionbag
Strength: 750 mg
Unit: 3 g
Volume in units: (Denmark 31.692) (Norway: 1.200) (Iceland: 10)
Each procurement number is a separate lot for the pharmaceutical indicated and is put up for tender independently of the other procurement numbers. This means that a tenderer may submit a tender for one, several or all procurement numbers (lots), and that framework agreements will be awarded separately for each procurement number. Reference is made to the tender specifications, including the provision on the list of products in general.
Under the title "quantity in units", an estimated consumption of the pharmaceuticals is indicated for each of the countries. It should be noted that this estimate corresponds to the historical consumption of the pharmaceuticals put up for tender and that suppliers must expect that the actual purchase under a framework agreement may deviate significantly from the estimate. Reference is made to paragraph 5.6 of the tender specifications and clause 4.2 in the framework agreement.
The Supplier must have authorisation to produce, import or receive pharmaceuticals for wholesale distribution within the EU/EEA.
The Pharmaceuticals shall be included in the Danish Medicines Agency’s list of medicine prices (“medicinpriser.dk”) and the Norwegian “Farmalogg” and the Icelandic “Lyfjaverðskrá” not later than 7 February 2022 in order to ensure supply from the beginning of the Purchase Period.
Procurement no.: 3
ATC Code: J01DD02
Generic name: Ceftazidime
Strength: 1 g
Unit: 4 g
Volume in units: (Denmark 1.625) (Norway: 4.000) (Iceland: 580)
ATC Code: J01DD02
Generic name: Ceftazidime
Strength: 2 g
Unit: 4 g
Volume in units: (Denmark 7.050) (Norway: 25.000) (Iceland: 2.010)
Each procurement number is a separate lot for the pharmaceutical indicated and is put up for tender independently of the other procurement numbers. This means that a tenderer may submit a tender for one, several or all procurement numbers (lots), and that framework agreements will be awarded separately for each procurement number. Reference is made to the tender specifications, including the provision on the list of products in general.
Under the title "quantity in units", an estimated consumption of the pharmaceuticals is indicated for each of the countries. It should be noted that this estimate corresponds to the historical consumption of the pharmaceuticals put up for tender and that suppliers must expect that the actual purchase under a framework agreement may deviate significantly from the estimate. Reference is made to paragraph 5.6 of the tender specifications and clause 4.2 in the framework agreement.
The Supplier must have authorisation to produce, import or receive pharmaceuticals for wholesale distribution within the EU/EEA.
The Pharmaceuticals shall be included in the Danish Medicines Agency’s list of medicine prices (“medicinpriser.dk”) and the Norwegian “Farmalogg” and the Icelandic “Lyfjaverðskrá” not later than 7 February 2022 in order to ensure supply from the beginning of the Purchase Period.
Procurement no.: 4
ATC Code: J01DD04
Generic name: Ceftriaxone
Strength: 1 g
Unit: 2 g
Volume in units: (Denmark 9.520) (Norway: 4.150) (Iceland: 5.666)
ATC Code: J01DD04
Generic name: Ceftriaxone
Strength: 2 g
Unit: 2 g
Volume in units: (Denmark 56.980) (Norway: 60.200) (Iceland: 4.231)
Each procurement number is a separate lot for the pharmaceutical indicated and is put up for tender independently of the other procurement numbers. This means that a tenderer may submit a tender for one, several or all procurement numbers (lots), and that framework agreements will be awarded separately for each procurement number. Reference is made to the tender specifications, including the provision on the list of products in general.
Under the title "quantity in units", an estimated consumption of the pharmaceuticals is indicated for each of the countries. It should be noted that this estimate corresponds to the historical consumption of the pharmaceuticals put up for tender and that suppliers must expect that the actual purchase under a framework agreement may deviate significantly from the estimate. Reference is made to paragraph 5.6 of the tender specifications and clause 4.2 in the framework agreement.
The Supplier must have authorisation to produce, import or receive pharmaceuticals for wholesale distribution within the EU/EEA.
The Pharmaceuticals shall be included in the Danish Medicines Agency’s list of medicine prices (“medicinpriser.dk”) and the Norwegian “Farmalogg” and the Icelandic “Lyfjaverðskrá” not later than 7 February 2022 in order to ensure supply from the beginning of the Purchase Period.
Procurement no.: 5
ATC Code: J01GB03
Generic name: Gentamicine
Strength: 1 mg/ml
Unit: 0,24 g
Volume in units: (Denmark 1.940) (Norway: 17.166) (Iceland: 400)
Each procurement number is a separate lot for the pharmaceutical indicated and is put up for tender independently of the other procurement numbers. This means that a tenderer may submit a tender for one, several or all procurement numbers (lots), and that framework agreements will be awarded separately for each procurement number. Reference is made to the tender specifications, including the provision on the list of products in general.
Under the title "quantity in units", an estimated consumption of the pharmaceuticals is indicated for each of the countries. It should be noted that this estimate corresponds to the historical consumption of the pharmaceuticals put up for tender and that suppliers must expect that the actual purchase under a framework agreement may deviate significantly from the estimate. Reference is made to paragraph 5.6 of the tender specifications and clause 4.2 in the framework agreement.
The Supplier must have authorisation to produce, import or receive pharmaceuticals for wholesale distribution within the EU/EEA.
The Pharmaceuticals shall be included in the Danish Medicines Agency’s list of medicine prices (“medicinpriser.dk”) and the Norwegian “Farmalogg” and the Icelandic “Lyfjaverðskrá” not later than 7 February 2022 in order to ensure supply from the beginning of the Purchase Period.
Procurement no.: 6
ATC Code: J01GB03
Generic name: Gentamicine
Strength: 3 mg/ml
Package: 80 ml
Unit: 0,24 g
Volume in units: (Denmark 24.580) (Norway: 62.620) (Iceland: 1.100)
Each procurement number is a separate lot for the pharmaceutical indicated and is put up for tender independently of the other procurement numbers. This means that a tenderer may submit a tender for one, several or all procurement numbers (lots), and that framework agreements will be awarded separately for each procurement number. Reference is made to the tender specifications, including the provision on the list of products in general.
Under the title "quantity in units", an estimated consumption of the pharmaceuticals is indicated for each of the countries. It should be noted that this estimate corresponds to the historical consumption of the pharmaceuticals put up for tender and that suppliers must expect that the actual purchase under a framework agreement may deviate significantly from the estimate. Reference is made to paragraph 5.6 of the tender specifications and clause 4.2 in the framework agreement.
The Supplier must have authorisation to produce, import or receive pharmaceuticals for wholesale distribution within the EU/EEA.
The Pharmaceuticals shall be included in the Danish Medicines Agency’s list of medicine prices (“medicinpriser.dk”) and the Norwegian “Farmalogg” and the Icelandic “Lyfjaverðskrá” not later than 7 February 2022 in order to ensure supply from the beginning of the Purchase Period.
Procurement no.: 7
ATC Code: J01GB03
Generic name: Gentamicine
Strength: 3 mg/ml
Package: 120 ml
Unit: 0,24 g
Volume in units: (Denmark 13.110) (Norway: 86.820) (Iceland: 1.350)
Each procurement number is a separate lot for the pharmaceutical indicated and is put up for tender independently of the other procurement numbers. This means that a tenderer may submit a tender for one, several or all procurement numbers (lots), and that framework agreements will be awarded separately for each procurement number. Reference is made to the tender specifications, including the provision on the list of products in general.
Under the title "quantity in units", an estimated consumption of the pharmaceuticals is indicated for each of the countries. It should be noted that this estimate corresponds to the historical consumption of the pharmaceuticals put up for tender and that suppliers must expect that the actual purchase under a framework agreement may deviate significantly from the estimate. Reference is made to paragraph 5.6 of the tender specifications and clause 4.2 in the framework agreement.
The Supplier must have authorisation to produce, import or receive pharmaceuticals for wholesale distribution within the EU/EEA.
The Pharmaceuticals shall be included in the Danish Medicines Agency’s list of medicine prices (“medicinpriser.dk”) and the Norwegian “Farmalogg” and the Icelandic “Lyfjaverðskrá” not later than 7 February 2022 in order to ensure supply from the beginning of the Purchase Period.
Procurement no.: 8
ATC Code: J01MA02
Generic name: Ciprofloxacin
Pharmaceutical form: Infusion fluid
Strength: 2 mg/ml
Package: 100 ml
Unit: 0,8 g
Volume in units: (Denmark 9.860) (Norway: 4.605) (Iceland: 60)
ATC Code: J01MA02
Generic name: Ciprofloxacin
Pharmaceutical form: Infusion fluid
Strength: 2 mg/ml
Package: 200 ml
Unit: 0,8 g
Volume in units: (Denmark 50.230) (Norway: 28.570) (Iceland: 1000)
Each procurement number is a separate lot for the pharmaceutical indicated and is put up for tender independently of the other procurement numbers. This means that a tenderer may submit a tender for one, several or all procurement numbers (lots), and that framework agreements will be awarded separately for each procurement number. Reference is made to the tender specifications, including the provision on the list of products in general.
Under the title "quantity in units", an estimated consumption of the pharmaceuticals is indicated for each of the countries. It should be noted that this estimate corresponds to the historical consumption of the pharmaceuticals put up for tender and that suppliers must expect that the actual purchase under a framework agreement may deviate significantly from the estimate. Reference is made to paragraph 5.6 of the tender specifications and clause 4.2 in the framework agreement.
The Supplier must have authorisation to produce, import or receive pharmaceuticals for wholesale distribution within the EU/EEA.
The Pharmaceuticals shall be included in the Danish Medicines Agency’s list of medicine prices (“medicinpriser.dk”) and the Norwegian “Farmalogg” and the Icelandic “Lyfjaverðskrá” not later than 7 February 2022 in order to ensure supply from the beginning of the Purchase Period.
Procurement no.: 9
ATC Code: J01XA01
Generic name: Vancomycin
Pharmaceutical form: Infusion fluid
Strength: 500 mg
Package:
Unit: 2 g
Volume in units: (Denmark 25.257) (Norway: 4.718) (Iceland: 10)
ATC Code: J01XA01
Generic name: Vancomycin
Pharmaceutical form: Infusion fluid
Strength: 1000 mg
Package:
Unit: 2 g
Volume in units: (Denmark 79.377) (Norway: 60.430) (Iceland: 9.832)
Each procurement number is a separate lot for the pharmaceutical indicated and is put up for tender independently of the other procurement numbers. This means that a tenderer may submit a tender for one, several or all procurement numbers (lots), and that framework agreements will be awarded separately for each procurement number. Reference is made to the tender specifications, including the provision on the list of products in general.
Under the title "quantity in units", an estimated consumption of the pharmaceuticals is indicated for each of the countries. It should be noted that this estimate corresponds to the historical consumption of the pharmaceuticals put up for tender and that suppliers must expect that the actual purchase under a framework agreement may deviate significantly from the estimate. Reference is made to paragraph 5.6 of the tender specifications and clause 4.2 in the framework agreement.
The Supplier must have authorisation to produce, import or receive pharmaceuticals for wholesale distribution within the EU/EEA.
The Pharmaceuticals shall be included in the Danish Medicines Agency’s list of medicine prices (“medicinpriser.dk”) and the Norwegian “Farmalogg” and the Icelandic “Lyfjaverðskrá” not later than 7 February 2022 in order to ensure supply from the beginning of the Purchase Period.